Bristol Myers Company Insiders

BMY Stock  USD 47.84  0.42  0.87%   
Slightly above 67% of Bristol Myers' corporate insiders are selling. The analysis of insiders' sentiment of trading Bristol Myers Squibb stock suggests that many insiders are alarmed at this time. Bristol Myers employs about 34.1 K people. The company is managed by 62 executives with a total tenure of roughly 344 years, averaging almost 5.0 years of service per executive, having 550.0 employees per reported executive.
Giovanni Caforio  Chairman
Chairman of the Board, Chief Executive Officer
Lamberto Andreotti  Chairman
Executive Chairman, Officer, Ex-Officio Member of Audit Committee, Ex-Officio Member of Committee on Directors and Corporate Governance and Ex-Officio Member of Compensation and Management Devel. Committee

Bristol Myers' Insider Buying Vs Selling

33

 
Selling
 
Buying

Latest Trades

2024-01-09Rick LarsenDisposed @ 51.27
2024-01-03Tommy TubervilleDisposed @ 52.3
2023-12-05Christopher S BoernerAcquired 2000 @ 49.78View
2023-11-28Christopher S BoernerAcquired 3071 @ 48.86View
2023-11-20Theodore R Samuels IIAcquired 8500 @ 49.81View
2023-11-16Tommy TubervilleDisposed @ 50.84
2023-10-24Greg StantonDisposed @ 56.12
2023-10-17Tommy TubervilleAcquired @ 57.38
2023-09-26Greg StantonAcquired @ 58.54
2023-08-24Ann PowellDisposed 17986 @ 61.25View
2023-08-22Dan SullivanDisposed @ 61.86
2023-08-03Robert M PlengeDisposed 732 @ 61.14View
2023-07-12Daniel S. GoldmanDisposed @ 62.27
2023-05-10Shelley Moore CapitoDisposed @ 68.49
2023-05-03Rupert VesseyDisposed 50385 @ 67.06View
Monitoring Bristol Myers' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Bristol Myers' insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Bristol Myers Squibb. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Bristol Myers' stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

Bristol Myers' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Bristol Myers' future performance. Based on our forecasts, it is anticipated that Bristol will maintain a workforce of slightly above 44000 employees by May 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Bristol Myers' latest congressional trading

Congressional trading in companies like Bristol Myers Squibb, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Bristol Myers by those in governmental positions are based on the same information available to the general public.
2024-01-03Senator Thomas H TubervilleAcquired Under $15KVerify
2023-09-26Representative Greg StantonAcquired Under $15KVerify
2023-05-10Senator Shelley M CapitoAcquired Under $15KVerify
2022-11-28Representative Van TaylorDisposed $100K to $250KVerify
2022-06-17Senator Shelley Moore CapitoAcquired Under $15KVerify
2022-01-18Senator Thomas R. CarperAcquired Under $15KVerify
2021-11-10Representative Carol Devine MillerDisposed $15K to $50KVerify
2021-10-28Representative Kim SchrierDisposed Under $15KVerify
2020-11-19Representative Kenny MarchantAcquired $15K to $50KVerify
2020-10-22Representative Katherine M. ClarkDisposed Under $15KVerify
2020-10-22Representative George HoldingDisposed Under $15KVerify
2020-04-16Senator David A Perdue , JrAcquired Under $15KVerify
2020-04-14Senator Kelly LoefflerAcquired $100K to $250KVerify
2020-03-18Representative Gilbert CisnerosDisposed Under $15KVerify
2019-04-08Representative Thomas SuozziDisposed Under $15KVerify
2018-12-28Senator Sheldon WhitehouseAcquired $15K to $50KVerify
2018-04-06Representative Carlos CurbeloAcquired Under $15KVerify
2017-01-20Senator John HoevenAcquired $50K to $100KVerify
2014-06-19Senator Susan M. CollinsAcquired Under $15KVerify
2014-06-19Senator Susan M CollinsAcquired Under $15KVerify

Bristol Myers Management Team Effectiveness

The company has Return on Asset of 0.0563 % which means that on every $100 spent on assets, it made $0.0563 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2653 %, implying that it generated $0.2653 on every 100 dollars invested. Bristol Myers' management efficiency ratios could be used to measure how well Bristol Myers manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Bristol Myers' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to rise to 0.14 in 2024, whereas Return On Tangible Assets are likely to drop 0.15 in 2024. At this time, Bristol Myers' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 66.6 B in 2024, whereas Other Assets are likely to drop slightly above 3.3 B in 2024.
Net Income Applicable To Common Shares is likely to rise to about 6 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 1.6 B in 2024.

Bristol Myers Workforce Comparison

Bristol Myers Squibb is number one stock in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 41,361. Bristol Myers totals roughly 34,100 in number of employees claiming about 82% of equities under Health Care industry.

Bristol Myers Profit Margins

The company has Net Profit Margin of 0.18 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.17 %, which entails that for every 100 dollars of revenue, it generated $0.17 of operating income.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.80.7624
Sufficiently Up
Slightly volatile
Operating Profit Margin0.250.3831
Way Down
Pretty Stable

Bristol Myers Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bristol Myers insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bristol Myers' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bristol Myers insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-06-01
0.5
1
2
 3,306 
 4,502 
2024-03-01
0.5746
77
134
 1,299,044 
 887,200 
2023-12-01
1.2857
18
14
 83,482 
 50,028 
2023-09-01
0.8182
9
11
 15,264 
 75,840 
2023-06-01
0.9412
16
17
 30,303 
 89,060 
2023-03-01
1.45
116
80
 1,372,082 
 1,197,512 
2022-12-01
1.7778
16
9
 76,139 
 101,217 
2022-09-01
1.1
11
10
 135,987 
 371,874 
2022-06-01
2.8571
20
7
 33,978 
 107,629 
2022-03-01
1.4583
105
72
 1,307,363 
 965,115 
2021-12-01
0.8667
13
15
 116,346 
 240,709 
2021-09-01
1.0
30
30
 403,897 
 794,971 
2021-06-01
1.1875
19
16
 39,854 
 94,914 
2021-03-01
1.2963
140
108
 1,328,695 
 658,778 
2020-12-01
0.871
27
31
 159,284 
 298,896 
2020-09-01
1.4286
20
14
 212,460 
 316,254 
2020-06-01
2.25
27
12
 100,259 
 46,619 
2020-03-01
1.1087
153
138
 1,850,402 
 1,237,584 
2019-12-01
11.5455
127
11
 2,125,296 
 66,385 
2019-09-01
14.0
14
1
 59,752 
 220.00 
2019-06-01
1.0769
14
13
 38,923 
 86,400 
2019-03-01
0.6296
102
162
 1,359,971 
 985,222 
2018-12-01
1.625
13
8
 18,753 
 20,002 
2018-09-01
1.2727
14
11
 8,787 
 28,444 
2018-06-01
1.1429
16
14
 40,659 
 48,875 
2018-03-01
1.2887
125
97
 1,126,758 
 794,390 
2017-12-01
1.7143
12
7
 171,144 
 328,464 
2017-09-01
2.2
11
5
 12,629 
 14,064 
2017-06-01
1.75
14
8
 113,954 
 63,675 
2017-03-01
0.8491
135
159
 1,434,652 
 1,292,500 
2016-12-01
1.2
12
10
 693,487 
 698,400 
2016-09-01
0.6111
11
18
 12,728 
 83,007 
2016-06-01
0.5161
16
31
 451,189 
 996,398 
2016-03-01
1.1687
194
166
 2,351,206 
 1,432,759 
2015-12-01
0.4375
7
16
 5,329 
 119,816 
2015-09-01
0.8333
10
12
 321,192 
 657,916 
2015-06-01
0.5
6
12
 34,707 
 80,775 
2015-03-01
1.3793
200
145
 2,213,345 
 1,889,360 
2014-12-01
0.6154
8
13
 25,235 
 384,689 
2014-09-01
0.5556
10
18
 90,304 
 353,237 
2014-06-01
1.25
10
8
 37,893 
 41,449 
2014-03-01
1.4214
226
159
 2,383,819 
 2,529,455 
2013-12-01
1.3333
8
6
 46,035 
 35,251 
2013-09-01
1.125
9
8
 24,861 
 184,595 
2013-06-01
0.4091
27
66
 1,148,469 
 2,830,626 
2013-03-01
1.1554
223
193
 2,658,929 
 3,053,939 
2012-12-01
0.3056
11
36
 589,294 
 1,054,973 
2012-09-01
0.3333
16
48
 965,673 
 2,041,572 
2012-06-01
0.1786
5
28
 20,745 
 153,556 
2012-03-01
1.2891
165
128
 1,901,514 
 1,279,129 
2011-12-01
0.4375
7
16
 502,411 
 1,106,499 
2011-09-01
1.1667
7
6
 729,052 
 726,921 
2011-06-01
0.2444
11
45
 1,255,062 
 3,022,207 
2011-03-01
0.9188
147
160
 2,320,390 
 1,794,777 
2010-12-01
0.8333
5
6
 13,585 
 56,533 
2010-09-01
0.4074
11
27
 252,545 
 912,952 
2010-06-01
0.5333
8
15
 84,718 
 495,254 
2010-03-01
0.8362
97
116
 1,986,576 
 1,572,207 
2009-12-01
0.25
4
16
 1,418 
 101,868 
2009-09-01
0.5714
4
7
 4,357 
 37,305 
2009-06-01
1.2
6
5
 43,455 
 12,830 
2009-03-01
1.1831
84
71
 4,628,862 
 820,311 
2008-12-01
1.2
6
5
 64,226 
 68,195 
2008-09-01
0.375
3
8
 1,579 
 48,764 
2008-06-01
3.4545
38
11
 418,379 
 406,408 
2008-03-01
1.5
48
32
 2,925,474 
 32,790 
2007-12-01
3.0
6
2
 2,757 
 19,399 
2007-09-01
0.5455
6
11
 2,802 
 51,486 
2007-06-01
0.68
17
25
 638,391 
 201,683 
2007-03-01
2.0
36
18
 1,135,518 
 25,011 
2006-12-01
7.5
15
2
 1,839,149 
 6,076 
2006-09-01
0.7273
8
11
 5,478 
 78,666 
2006-06-01
1.3
13
10
 22,389 
 15,850 
2006-03-01
1.6739
77
46
 2,113,360 
 611,800 
2005-12-01
2.2
11
5
 266,812 
 40,141 
2005-09-01
2.5
10
4
 209,934 
 3,986 
2005-06-01
2.0
20
10
 83,508 
 29,934 
2005-03-01
3.4667
52
15
 1,929,595 
 364,819 
2004-12-01
2.25
9
4
 37,649 
 13,165 
2004-09-01
1.7143
12
7
 158,149 
 112,791 
2004-06-01
3.0
21
7
 44,649 
 21,954 
2004-03-01
6.1111
55
9
 1,850,467 
 208,601 
2003-12-01
9.0
9
1
 24,904 
 5,127 
2003-09-01
6.6667
20
3
 414,912 
 52,034 
1998-03-01
0.4
4
10
 72,750 
 126,648 

Bristol Myers Notable Stakeholders

A Bristol Myers stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bristol Myers often face trade-offs trying to please all of them. Bristol Myers' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bristol Myers' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Giovanni CaforioChairman of the Board, Chief Executive OfficerProfile
Lamberto AndreottiExecutive Chairman, Officer, Ex-Officio Member of Audit Committee, Ex-Officio Member of Committee on Directors and Corporate Governance and Ex-Officio Member of Compensation and Management Devel. CommitteeProfile
Adam DubowSenior Vice President, Chief Compliance Officer and Ethics Officer, Member of the Leadership TeamProfile
John ElickerSenior Vice President - Corporate Affairs and Investor RelationsProfile
Karen SantiagoSenior Vice President, Corporate ControllerProfile
Rupert VesseyExecutive Vice President - Research and Early Development, Member of the Leadership TeamProfile
Emmanuel BlinSenior Vice President Chief Strategy OfficerProfile
Joseph CaldarellaSenior Vice President Corporate ControllerProfile
Murdo GordonExecutive Vice President Chief Commercial OfficerProfile
Ann JudgeChief Human Resource Officer, Senior Vice President Member of the Leadership TeamProfile
Sandra LeungExecutive Vice President, General Counsel, Member of the Leadership TeamProfile
Paul AutenriedExecutive Vice President, Chief Information Officer, Member of the Leadership TeamProfile
Samit HirawatExecutive Vice President, Chief Medical Officer, Global Drug Development, Member of the Leadership TeamProfile
Francis CussExecutive Vice President Chief Scientific OfficerProfile
Paul BiondiSenior Vice President, Head of Strategy & Business DevelopmentProfile
Kathryn MetcalfeExecutive Vice President - Corporate Affairs Member of the Leadership TeamProfile
Elizabeth MilyExecutive Vice President - Strategy and Business Development, Member of the Leadership TeamProfile
Ann PowellChief Human Resource Officer, Senior Vice President, Member of the Leadership TeamProfile
Charles BancroftChief Financial Officer, Executive Vice President - Global Business OperationsProfile
Louis SchmuklerExecutive Vice President, President - Global Product Development and Supply, Member of the Leadership TeamProfile
Christopher BoernerExecutive Vice President and Chief Commercial Officer, Member of the Leadership TeamProfile
David ElkinsExecutive Vice President and Chief Financial Officer Member of the Leadership TeamProfile
Anne NielsenSenior Vice President Chief Compliance and Ethics OfficerProfile
Joseph EidSenior Vice President and Head of Global Medical Affairs, Member of the Leadership TeamProfile
Thomas LynchChief Scientific Officer, Executive Vice PresidentProfile
Samuel MoedSenior Vice President - Strategic Planning and AnalysisProfile
Togo WestIndependent DirectorProfile
Michael BonneyIndependent DirectorProfile
Alan LacyIndependent DirectorProfile
Robert BertoliniIndependent DirectorProfile
Jose BaselgaIndependent DirectorProfile
Michael GrobsteinIndependent DirectorProfile
Phyllis YaleIndependent DirectorProfile
Matthew EmmensIndependent DirectorProfile
Peter ArduiniIndependent DirectorProfile
Karen VousdenIndependent DirectorProfile
Gerald StorchIndependent DirectorProfile
Vicki SatoLead Independent DirectorProfile
Manuel MedinaIndependent DirectorProfile
Julia HallerIndependent DirectorProfile
Laurie GlimcherIndependent DirectorProfile
Lewis CampbellIndependent DirectorProfile
Dinesh PaliwalIndependent DirectorProfile
Theodore SamuelsLead Independent DirectorProfile
Adam LenkowskyChief VPProfile
Jitendra TyagiHead IndiaProfile
Catherine OwenSenior MarketsProfile
BCH BMEx DevelProfile
Nadim AhmedExecutive Vice President and President - HematologyProfile
Cari GallmanVP OfficerProfile
Ahn PooleExecutive OfficerProfile
Tim PowerVice President of Investor RelationsProfile
Giovanni MDExecutive BoardProfile
Greg MeyersExecutive Vice President Chief Digital and Technology Officer, Member of the Leadership TeamProfile
Michelle WeeseExecutive Vice President - Corporate Affairs, Member of the Leadership TeamProfile
Joseph EidenHead AffairsProfile
Paula PriceIndependent DirectorProfile
Sandra EsqExecutive CounselProfile
Kimberly JablonskiChief OfficerProfile
Derica RiceIndependent DirectorProfile
Timothy PowerVP RelationsProfile
Samit MDExecutive DevelopmentProfile

About Bristol Myers Management Performance

The success or failure of an entity such as Bristol Myers Squibb often depends on how effective the management is. Bristol Myers management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bristol management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bristol management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.17  0.15 
Return On Capital Employed 0.24  0.29 
Return On Assets 0.08  0.14 
Return On Equity 0.27  0.30 
The data published in Bristol Myers' official financial statements usually reflect Bristol Myers' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Bristol Myers Squibb. For example, before you start analyzing numbers published by Bristol accountants, it's critical to develop an understanding of what Bristol Myers' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Bristol Myers' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bristol Myers' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Bristol Myers' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bristol Myers Squibb. Please utilize our Beneish M Score to check the likelihood of Bristol Myers' management manipulating its earnings.

Bristol Myers Workforce Analysis

Traditionally, organizations such as Bristol Myers use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bristol Myers within its industry.

Bristol Myers Manpower Efficiency

Return on Bristol Myers Manpower

Revenue Per Employee1.3M
Revenue Per Executive725.9M
Net Income Per Employee235.8K
Net Income Per Executive129.7M
Working Capital Per Employee278.8K
Working Capital Per Executive153.4M
When determining whether Bristol Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for Bristol Stock analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Commodity Directory
Find actively traded commodities issued by global exchanges
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Stocks Directory
Find actively traded stocks across global markets
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.09)
Dividend Share
2.31
Earnings Share
3.86
Revenue Per Share
21.753
Quarterly Revenue Growth
0.006
The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.